CYTK
CytokineticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Successful regulatory feedback and positive clinical readouts lead to accelerated development/partner milestones; market awards a premium for near-term commercial optionality and partnership upside.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -21.9.
What can break
Unfavorable FDA guidance, failed readouts, or a tightened cash runway force dilution or partnership concessions; shares reprice materially lower.
Momentum
63
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.37 · Bull $4.28 · Bear $2.14
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $108.47
Why
Momentum63 · Δ7d -21.9
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
63
26% active weight
Current posture
7d trendSoftening
Δ7d
-21.9
Δ21d
-2.0
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 63.2 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$10.09B
Beta
0.54
Shares Out
124.43M
P/E (TTM) · Derived
-12.4
P/S (TTM)
85.88
P/FCF (TTM) · Derived
-17.94
Rev YoY
+1125.8%
EPS YoY
+22.7%
Gross Margin
+87.0%
Op Margin
-796.0%
Net Debt
$398.91M
Current Ratio
4.21
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology